KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.85

Efficacy of imiquimod in the management of lentigo maligna.

Marie Daude, Monica Dinulescu, Jean-Michel Nguyen, Hervé Maillard, Florence Le Duff, Laurent Machet, Marie Beylot-Barry, Delphine Legoupil, Ewa Wierzbicka-Hainaut, Christophe Bedane, Marie Thérèse Leccia, Sébastien Debarbieux, Nicolas Meyer, Sandrine Monestier, Guido Bens, Marc G Denis, Celine Bossard, Beatrice Vergier, Amir Khammari, Brigitte Dréno

J Eur Acad Dermatol Venereol 37(9) 1785-1791

PMID37114291
PMCID-
DOI10.1111/jdv.19141
发表日期2023-04-28
入排依据:The trial is a phase III RCT in oncology (lentigo maligna) with a drug intervention, but it lacks a primary or key secondary time-to-event efficacy endpoint with reported time-to-event data (e.g., Kaplan-Meier, HR). The primary endpoint is surgical success, and secondary endpoints do not include reported time-to-event outcomes.
摘要

摘要

BACKGROUND: Lentigo maligna (LM) is a melanocytic proliferation occurring on photo-exposed skin that may progress to LM melanoma. Surgery is recommended as first-line treatment. Excision margins of 5-10 mm remain, without international consensus. Several studies have shown that imiquimod, an immunomodulator, induces LM regression. This study investigated the effect of imiquimod versus placebo in neoadjuvant settings. PATIENTS AND METHODS: We performed a prospective, randomized, multicentre, phase III clinical study. Patients were randomly assigned in 1:1 ratio to receive imiquimod or placebo for 4 weeks, followed by LM excision 4 weeks after the last application of imiquimod or placebo. The primary endpoint was extra-lesional excision, with a 5 mm margin from the residual pigmentation after imiquimod or vehicle. Secondary endpoints included the gain on the surface removed between the two groups; number of revision surgeries to obtain extra-lesional excisions; relapse-free time; and number of complete remissions after treatment. RESULTS: A total of 283 patients participated in this study; 247 patients, 121 patients in the placebo group and 126 in the imiquimod group, accounted for the modified ITT population. The first extralesional extirpation was performed in 116 (92%) imiquimod patients and in 102 (84%) placebo patients; the difference was not significant (p = 0.0743). Regarding the surface of LM, imiquimod reduced the LM surface (4.6-3.1 cm2 ) significantly (p < 0.001) more compared to the placebo (3.9-4.1 cm2 ). CONCLUSION: Imiquimod reduces the lentigo maligna surface after 1 month of treatment, without a higher risk of intralesional excision and with a positive aesthetic outcome.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。